JAMA reports fluvoxamine as potential early treatment for COVID-19
SAN FRANCISCO – Nov. 12, 2020 – The COVID-19 Early Treatment Fund (CETF), today announced that JAMA, The Journal of the American Medical Association, published the results of a Washington University School of Medicine in St. Louis double-blind, randomized controlled clinical trial that investigated whether the antidepressant medication fluvoxamine, if taken within seven days of…